poisar

Stocks · News reference

UBS Maintains Buy on Natera, Raises Price Target to $435

Benzinga Newsdesk

UBS analyst Doug Schenkel maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $290 to $435.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NTRA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Eric Volkman

    This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy?

    Stanley Druckenmiller's Duquesne family office has maintained Natera as its largest holding for 8 consecutive quarters. The medical diagnostics company uses liquid biopsy technology for cancer detection and other applications, showing strong growth with 57% year-over-year increase in oncology tests and 38% revenue growth. Despite persistent losses, the company has strong cash reserves and is projected to approach profitability by 2027. However, the stock has surged 87% in the past year with a lofty price-to-sales ratio of 17.

    NTRALLYMETADAL
  2. Brett Schafer

    Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia)

    Billionaire investor Stanley Druckenmiller holds positions in Amazon and Alphabet for AI infrastructure exposure, but his largest U.S. stock holding is Natera, a genetic diagnostics company that has returned approximately 10x since his initial investment in Q3 2022. Druckenmiller sold his Nvidia position in early 2024 due to valuation concerns and now holds Taiwan Semiconductor Manufacturing as his AI semiconductor bet instead.

    AMZNGOOGGOOGLGOOGMGOOGN